Talk:Rotigotine

This is the talk page for discussing improvements to the Rotigotine article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Rotigotine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The original creator of NEUPRO PATCH

The original creators of the neupro patch was Aderis Pharmaceuticals represented by Gevork Minaskanian, Ph.D., Noel J. Cusack, Ph.D., James V. Peck, Pharm D.,William S. Wheeler, M.D., and Kenneth L. Rice Jr., M.B.A., J.D. Their creation was sold to schwartz pharma that was later bought by UCB. —Preceding unsigned comment added by 204.8.204.116 (talk) 01:18, 12 October 2007 (UTC)[reply]

Binding profile clarification needed

The receptor binding profile lists a certain D2 affinity but it needs to be clarified as separate affinities for: D2S, D2L, and D2VL. The functions of those different D2 receptors are dramatically different than each other. I would assume that the given D2 affinity specified is for D2L, but this should be specified, and the D2S and D2VL affinities are very important information. 162.89.0.47 (talk) —Preceding undated comment added 17:14, 11 April 2017 (UTC)[reply]